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Introduction
Monosegment Associating Liver Partition and Portal Vein 
ligation for Staged hepatectomy (ALPPS) was defined 
by Schadde et al. as a liver resection leaving a remnant 
constituted of one single segment ± segment 1 (S1) (1). This 
variation of the ALPPS technique represents a substantial 
change to the traditional paradigm of liver resectability, 
which is defined as the removal of tumour with negative 
margins, preserving ≥2 contiguous liver segments along 
with their inflow, outflow and biliary drainage. Various 
reports and reviews have been published, describing 
advantages and limitations of ALPPS (1-3). ALPPS induces 
a rapid hypertrophy of the liver remnant compared to portal 
vein embolization or ligation with a rate of completion of 
second stage between 95% and 100%. However, concerns 
are mainly due to the high morbidity (up to 44% of 
Clavien-Dindo grade III or more) and mortality rates up 
to 29%, as well as the possible relationship between a rapid 
hypertrophy and tumour progression (3). Therefore, ALPPS 
is still a debated topic. Monosegment ALPPS hepatectomy 
overcomes left and right trisectionectomy, which are the 
most extensive liver resections according to the terminology 
introduced by the IHPBA (4), with the intent of offering 
an oncological resection and a lower incidence of post-
hepatectomy liver failure (PHLF). Prior to the introduction 
of ALPPS, the treatment of bilobar borderline resectable 
liver metastases with single segment remnants could only be 
achieved by the means of two-stage hepatectomies (TSH), 
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but often requiring very long intervals to achieve a sufficient 
FLR. Alternatively, the option of ultrasound-guided 
multiple wedge resections aimed to maximize parenchymal-
sparing and to allow curative resection in one stage (5,6). 
However, the ALPPS technique has not yet been 
standardized. Different types of monosegment ALPPS 
hepatectomy have been described by Schadde et al., who 
proposed a nomenclature based on the segment of the liver 
remnant rather than the segments of resected liver (2). 
In this report, we present our preliminary experience on 
segment 4+1 monosegment ALPPS hepatectomy and a 
review of the literature of published similar cases.
Methods
Literature search 
PubMed database was searched from inception to 
23/10/2016. The following search terms were used: Text 
words [monosegment*] AND [ALPPS*] OR [Associating 
Liver Partition and Portal Vein ligation for Staged 
hepatectomy*]. Three results were yielded in total from the 
initial search. 
Definitions 
Segments were defined according to the classic Couinaud’s 
anatomical division of the liver (7). Monosegment 
resection was defined as a liver resection leaving a remnant 
constituted of 1 single segment ±S1 (2). The cut-off for 
the minimal safe size of the liver remnant after single 
stage hepatectomy was set as >30% of the TLV for 
patients with chemotherapy-related liver injury (8). Post-
hepatectomy liver failure (PHLF) was defined according to 
the International Study Group of Liver Surgery (ISGLS) 
classification (increased INR or need of clotting factors to 
maintain normal INR and hyperbilirubinemia on or after 
postoperative day 5) (9). Postoperative complications were 
graded according to the Clavien-Dindo classification (10). 
Patients
Two patients underwent segment 4+1 ALPPS hepatectomy 
at Aberdeen Royal Infirmary (UK). The first patient 
was a 61-year-old female with no comorbidities. She 
presented with adenocarcinoma of the right colon with 
synchronous bilobar liver metastases. The preoperative 
CT and MRI liver showed 7 lesions in segments 5, 7 and 8 
and in the left lobe, where the largest, measuring 3.4 cm, 
was at the passage between S2 and S3. She underwent 
right hemicolectomy, and the primary was staged as 
Duke’s D pT3N1. After chemotherapy with four cycles of 
Capecitabine and Oxaliplatin (XELOX), a partial response 
was observed. Technically, the right hemiliver and the left 
lateral sector could not be preserved due to the involvement 
of the right hepatic vein and the large lesion in S2−3. The 
preoperative FLR volume for segments 4+1 was 199 cm3, 
13% of total liver volume (TLV), which was deemed too 
small for a single stage procedure (Figure 1). 
The second patient was a 61-years-old male presenting 
with mid rectum adenocarcinoma treated with neoadjuvant 
pelvic radiotherapy, chemotherapy with XELOX and 
anterior resection with loop ileostomy (stage pT2N1 Duke’s 
C). He received postoperative Capecitabine alone and 
unfortunately developed serious drug-induced neuropathy 
and pulmonary embolism (PE), which required therapeutic 
dose anticoagulation and contraindicated any further 
chemotherapy. Six months after resection of the primary 
tumor, he developed a total of 7 bilobar liver metastases, 
located in segments 2, 3, 5, 6 and 8. The maximum diameter 
of the largest lesion was 3cm, deep in S6 close to the 
sectorial division of the right portal vein. Only segment 7, 4 
and 1 were clear from lesions. He could not receive further 
chemotherapy, and he was offered ALPPS as a rescue 
approach. The preoperative FLR volume for segments 
4 and 1 was 255 cm3, 14% of TLV, which was deemed 
insufficient to undergo one-stage hepatectomy (Figure 2). 
For both patients, alternative treatment strategies were 
evaluated in our institutional Hepatobiliary and Pancreatic 
Multidisciplinary Meeting (HPB-MDT). Both patients 
were informed about surgical and nonsurgical options and 
gave informed consent to undergo two-stage hepatectomy 
with ALPPS technique. 
Technique 
First stage consisted in a left lateral sectionectomy with 
intra-glissonian dissection of the vascular elements 
assuring the preservation of the artery for segment 4 
and its glissonian pedicle. The right portal vein was then 
ligated and the Cantlie line used as the mark for the right-
sided transection. Parenchymal transection was performed 
using Thunderbeat® (Olimpus) device, whereas clips and 
ligatures were used for vascular and bile ducts larger than 
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2 mm in diameter. No vascular occlusion was performed. 
A fibrin sealant patch (TachoSil®) was used to cover the 
transection area. 
Second stage consisted of the division of right hepatic 
vein (RHV) and artery (RHA) and right glissonian pedicle 
with Vascular Endo GIATM with removal of the right 
hemiliver.
Imaging
Patients were investigated with a preoperative MRI, a triple 
phase CT and liver volumetry preoperatively, after first 
stage and postoperatively as part of the follow up. Liver 
volumes were calculated using FIJI® CT volumetry software 
on the portal phase. 
Figure 1 Preoperative triple phase CT liver in patient 1.
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Results
Institutional experience
The preoperative volumetry showed total liver volumes of 
1,840 and 1,634 cm3. The volume of the FLR, constituted 
of segment 4+1, was 255 cm3 (patient 1) and 199 cm3 
(patient 2). After first stage, a significant FLR growth was 
observed in both patients: the CT scan prior to stage 2 
showed an increase by 165% (255 to 677 cm3) and 241% 
(199 to 679 cm3), respectively. Second stage was performed 
after 9 and 14 days, respectively (Figures 3,4). First-stage 
lasted 6 and 5.5 hours in patient 1 and 2, and both had 
blood losses above 2,000 mL, requiring intraoperative blood 
transfusions. Between stages, both patients developed grade 
A PHLF, not requiring any change in their management. 
After second-stage both developed mild ascites, which 
recovered with conservative treatment. Both patients 
developed a subphrenic intraabdominal collection after 
second stage, and they required percutaneous drainage. 
These complications were scored grade IIIa Clavien-Dindo. 
No 90-day mortality was observed. Histopathology showed 
a complete resection (R0) in both cases. Both patients are 
still alive after 20 and 27 months, respectively, with no 
evidence of recurrent disease (Figures 5,6).
Review of the literature
The literature search provided three results, including 
an original article and two case reports. Schadde et al. (2) 
analyzed retrospectively the ALPPS Registry for all 
monosegment ALPPS. In this series 12 patients underwent 
monosegment ALPPS and 6 of them were segment 4±1 
ALPPS. One of the two case reports was already been 
included within the series published by Schadde (11). 
Montalvá Orón et al. reported the case of a 65-year-
old patient with CRLM who underwent segment 4+1 
ALPPS (12). Table 1 shows intraoperative details and 
volumetrics for the seven cases from the literature and our 
two patients for comparison. Our cases had a lower baseline 
FLR and a higher FLR before stage 2 compared to the 
median values from the literature. Likewise, there was an 
increase in FLR/BW ratio from 0.31 to 0.84 in patient 1 and 
from 0.22 to 0.76 in patient 2, compared to median values 
of 0.42 and 0.69 respectively at baseline and prior to stage 2 
Figure 2 Preoperative triple phase CT liver in patient 2.
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in the data from the literature. Median overall survival (OS) 
for the 7 cases reported in the literature was 13 months 
(range, 5–24 months). Median disease free survival (DFS) 
was 5 months (range, 3–23 months), as shown in Table 2: 
three out of 7 patients did not present recurrence after 5, 13 
and 23 months of follow up. Three patients recurred within 
6 months: two to the liver and extrahepatic recurrence and 
one patient with brain metastases. Another patient presented 
recurrent disease only after 12 months of follow up.
Discussion
The two patients presented above had extensive multifocal 
bilobar CRLM, presenting with more than 6 lesions 
distributed in less than 6 segments, but with the possibility 
of a complete oncological resection with negative margins 
(R0). Therefore, they were considered technically resectable 
with a two stage hepatectomy (left lobe wedge resections 
and right hepatectomy) or a monosegment ALPPS. A two 
stage hepatectomy was technically feasible but, similarly 
Figure 3 Before second stage triple phase CT liver showing increase of FLR in patient 1.
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to the cases reported in the literature, the right hemiliver 
and the LLS could not be retained as part of the FLR and 
wedge resections of the LLS were considered oncologically 
inadequate. Monosegment ALPPS was chosen as a salvage 
procedure with the aim to avoid the risk of drop-out due to 
inadequate hypertrophy or progression between stages. 
Monosegment 4+1 ALPPS hepatectomy in the two cases 
reported allowed obtaining an oncological clearance of the 
liver with acceptable costs in term of morbidity and good 
long-term outcomes. 
In the literature, the technique of monosegment ALPPS 
resection was initially presented as a case report by De 
Santibanes et al., and then described by Schadde et al. in a 
subanalysis of the ALPPS Registry (2,11). From a technical 
point of view, we used the same technique, avoiding the 
utilization of a plastic sheath on the transection plane and 
using TachoSil® instead. This decision was made to prevent 
the need for a surgical removal in case of impossibility to 
proceed to second stage. 
In ALPPS the observed median kinetic growth is 0.02 
sFLR per day (interquartile range, 0.01–0.03), which means 
that a patient with an initial FLR of 15% could achieve the 
volume cut-off of 30% within 15 days after stage 1 (13). It 
would require about six weeks to get the same results after 
TSH, when the liver volume only increases by 2% per 
week. Furthermore, the risk of cancellation of second stage 
because of insufficient growth of FLR or further intra or 
extra-hepatic spread of the disease in the waiting time is 
more than 35% with TSH (2,4). Overall, ALPPS induces a 
growth of FLR of approximately 80% in 7 days (range, 6– 
13 days) with only 3% of patients not undergoing the 
second stage (13). In our experience of monosegment 4±1 
ALPPS and in the literature, second stage was performed in 
all cases, achieving a complete oncological resection. 
The present manuscript  and the review of  the 
literature report encouraging oncological outcomes for 
monosegmental 4±1 ALPPS. Considering all nine cases, 
overall median disease free survival was 8.5 months (3– 
27 months) and 5 out of 9 patients did not present any 
recurrence during their follow up. However, some patients 
recurred within 6 months with local or extrahepatic disease. 
Early postoperative recurrence or disease progression in less 
than 6 months might reflect both a failure of the treatment 
and a very aggressive biology of the tumor. 
Figure 4 Before second stage triple phase CT liver showing increase of FLR in patient 2.
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Olthof et al. showed that ALPPS had the same outcomes 
as palliative chemotherapy in patients with at least 2 of the 
following criteria: ≥6 metastases, ≥2 future liver remnant 
metastases, ≥6 involved segments excluding segment 1 (14). 
These results might help in the selection of patients to 
exclude from ALPPS because of advanced disease, although 
our two patients met only one of the criteria. However, 
the number of cases is too small to draw any definitive 
conclusions regarding the oncological outcomes of 
monosegment ALPPS. 
Monosegment ALPPS might prove of benefit in the 
future for patients with lesions in proximity of main 
vascular structures for which a progression in size between 
stages would compromise the resection. In this group of 
patients, it seems reasonable to offer an operation with the 
highest rate of hypertrophy and a completion of stages in 
the shortest interval possible. Therefore, in our opinion 
monosegmental ALPPS may represent an appropriate 
option in a selected group of patients. 
To date, monosegment ALPPS is not a standard 
technique in the treatment of bilateral CRLM. Pringle 
manoeuvre, diseased liver parenchyma (steatosis, fibrosis, 
chemotherapy-related changes) and age greater than 
60 years may negatively affect kinetic growth (13)
 
and 
consequently, postoperative outcomes. Bell and colleagues 
recently investigated the impact of advancing age on short 
Figure 5 Patient 1 follow up triple phase CT with no evidence of recurrence. 
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and long term outcomes after major surgery for colorectal 
liver metastases. Choosing a cut off of 75 years of age, 
they showed that the elderly group had greater morbidity 
(P=0.048), whereas marginally statistically significant. 
The 90-day mortality compared to the <75 group when 
performing a major hepatectomy of three or more segments 
was similar in both groups (15). Considering the increase 
in life expectancy in the western population and the good 
functional status of many people over 60 there is an open 
discussion about the differences between chronological and 
biological age (16). Our two patients were aged 61 at the 
time of surgery, which is one of the risk factors identified in 
the ALPPS Registry for poor postoperative outcomes, but 
they both had a good performance status, without major 
cardiovascular or respiratory comorbidities to contraindicate 
major surgery.
Several factors such as experience of each centre, age 
and patients’ comorbidities should be considered before 
choosing between TSH and Monosegment ALPPS (17,18). 
A recent retrospective case-match analysis of ALPPS and 
TSH for CRLM showed that there was no difference in 
feasibility and completion of treatment. ALPPS patients 
had a shorter interval between stages, but at the expense of 
increased overall and major complications. Interestingly, 
patients undergoing TSH who matched out from the 
analysis had a higher ASA score, more lesions and received 
less chemotherapy than the subgroup used for the matched 
analysis (19). Those results may confirm that, to date, 
ALPPS is performed in patients with better performance 
status and fewer comorbidities and who required more 
chemotherapy to achieve resectability. Therefore, even 
though good results have been achieved so far, prospective 
Figure 6 Patient 2 follow up triple phase CT with no evidence of recurrence.
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and randomized studies are needed to clarify the criteria to 
select the best candidate for ALPPS. 
Conclusions
Our results, along with the review of the literature, suggest 
that the monosegment 4±1 ALPPS procedure is feasible 
and effective in selected patients. Therefore, it could be a 





Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Informed Consent: Written informed consent was obtained 
from the patient for publication of this Case report and any 
accompanying images. 
References
1. Schadde E, Schnitzbauer AA, Tschuor C, et al. Systematic 
review and meta-analysis of feasibility, safety, and efficacy 
of a novel procedure: associating liver partition and portal 
vein ligation for staged hepatectomy. Ann Surg Oncol 
2015;22:3109-20. 
2. Schadde E, Malago M, Hernandez-Alejandro R, et 
al. Monosegment ALPPS hepatectomy: extending 
resectability by rapid hypertrophy. Surgery 
2015;157:676-89.
3. Lau WY, Lai EC, Lau SH. Associating liver partition and 
portal vein ligation for staged hepatectomy: the current 
role and development. Hepatobiliary Pancreat Dis Int 
2017;16:17-26.
4. Terminology Committee of the IHPBA. Terminology of 
liver anatomy and resections. HPB Surg 2000;2:333-9.
5. Adam R, Laurent A, Azoulay D, et al. Two-stage 
hepatectomy: A planned strategy to treat irresectable liver 
tumors. Ann Surg 2000;232:777-85.
6. Torzilli G, Procopio F, Botea F, et al. One-stage 
ultrasonographically guided hepatectomy for multiple 
bilobar colorectal metastases: a feasible and effective 




























































































































































































































































































































































































































HepatoBiliary Surgery and Nutrition, Vol 7, No 2 April 2018 115
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2018;7(2):105-115hbsn.amegroups.com
2009;146:60-71.
7. Bismuth H. Surgical anatomy and anatomical surgery of 
the liver. World J Surg 1982;6:3-9.
8. Nordlinger B, Van Cutsem E, Gruenberger T, et al. 
Combination of surgery and chemotherapy and the role of 
targeted agents in the treatment of patients with colorectal 
liver metastases: recommendations from an expert panel. 
Ann Oncol 2009;20:985-92.
9. Rahbari NN, Garden OJ, Padbury R, et al. 
Posthepatectomy liver failure: a definition and grading by 
the International Study Group of Liver Surgery (ISGLS). 
Surgery 2011;149:713-24. 
10. Dindo D, Demartines N, Clavien PA. Classification of 
surgical complications: a new proposal with evaluation in 
a cohort of 6336 patients and results of a survey. Ann Surg 
2004;240:205-13.
11. de Santibañes M, Alvarez FA, Santos FR, et al. The 
associating liver partition and portal vein ligation for 
staged hepatectomy approach using only segments I and 
IV as future liver remnant. J Am Coll Surg 2014;219:e5-9.
12. Montalvá Orón EM, Maupoey Ibáñez J, Bañuelos Carrillo 
R, et al. Monosegment ALPPS: A new variant of the 
techniques for rapid hepatic regeneration. Critical review 
of the initial results of our series. Cir Esp 2015;93:436-43. 
13. Schadde E, Ardiles V, Robles-Campos R, et al. Early 
survival and safety of ALPPS: first report of the 
International ALPPS Registry. Ann Surg 2014;260:829-36; 
discussion 836-8.
14. Olthof PB, Huiskens J, Wicherts DA, et al. Survival after 
associating liver partition and portal vein ligation for 
staged hepatectomy (ALPPS) for advanced colorectal liver 
metastases: A case-matched comparison with palliative 
systemic therapy. Surgery 2017;161:909-19.
15. Bell R, Pandanaboyana S, Nisar S, et al. The Impact of 
Advancing Age on Recurrence and Survival Following 
Major Hepatectomy for Colorectal Liver Metastases. J 
Gastrointest Surg 2017;21:266-74.
16. Turner NJ, Haward RA, Mulley GP, et al. Cancer in old 
age--is it inadequately investigated and treated? BMJ 
1999;319:309-12.
17. Al-Refaie WB, Parsons HM, Henderson WG, et al. 
Major cancer surgery in the elderly: results from the 
American College of Surgeons National Surgical Quality 
Improvement Program. Ann Surg 2010;251:311-8.
18. Farges O, Goutte N, Bendersky N, et al. Incidence and 
risks of liver resection: an all-inclusive French nationwide 
study. Ann Surg 2012;256:697-704; discussion 704-5.
19. Ratti F, Schadde E, Masetti M, et al. Strategies to 
Increase the Resectability of Patients with Colorectal 
Liver Metastases: A Multi-center Case-Match Analysis of 
ALPPS and Conventional Two-Stage Hepatectomy. Ann 
Surg Oncol 2015;22:1933-42.
Cite this article as: Soggiu F, Giovinazzo F, Straiton J, Turri G, 
Phillips J, Al-Kari B, Ahmed I, Habib M. Monosegment 
ALPPS hepatectomy preserving segment 4 for colorectal liver 
metastases: literature review and our experience. HepatoBiliary 
Surg Nutr 2018;7(2):105-115. doi: 10.21037/hbsn.2017.03.12
